JP2022501428A5 - - Google Patents
Info
- Publication number
- JP2022501428A5 JP2022501428A5 JP2021539483A JP2021539483A JP2022501428A5 JP 2022501428 A5 JP2022501428 A5 JP 2022501428A5 JP 2021539483 A JP2021539483 A JP 2021539483A JP 2021539483 A JP2021539483 A JP 2021539483A JP 2022501428 A5 JP2022501428 A5 JP 2022501428A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence shown
- hcdr3
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732299P | 2018-09-17 | 2018-09-17 | |
| US201862732334P | 2018-09-17 | 2018-09-17 | |
| US62/732,299 | 2018-09-17 | ||
| US62/732,334 | 2018-09-17 | ||
| PCT/US2019/051529 WO2020061059A1 (en) | 2018-09-17 | 2019-09-17 | Anti-lilrb2 antibodies and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501428A JP2022501428A (ja) | 2022-01-06 |
| JPWO2020061059A5 JPWO2020061059A5 (https=) | 2022-09-29 |
| JP2022501428A5 true JP2022501428A5 (https=) | 2022-09-29 |
Family
ID=69888746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539483A Pending JP2022501428A (ja) | 2018-09-17 | 2019-09-17 | 抗ｌｉｌｒｂ２抗体およびその使用の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12157768B2 (https=) |
| EP (1) | EP3852805A4 (https=) |
| JP (1) | JP2022501428A (https=) |
| KR (1) | KR20210108940A (https=) |
| CN (1) | CN113543804A (https=) |
| AU (1) | AU2019343131A1 (https=) |
| CA (1) | CA3111862A1 (https=) |
| WO (1) | WO2020061059A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202428604A (zh) | 2018-07-09 | 2024-07-16 | 美商戊瑞治療有限公司 | 結合至ilt4的抗體 |
| WO2021126906A1 (en) * | 2019-12-20 | 2021-06-24 | Merck Sharp & Dohme Corp. | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
| US11834512B2 (en) | 2020-05-04 | 2023-12-05 | The Regents Of The University Of California | Inhibiting anti-ENPP1 antibodies |
| MX2023003186A (es) * | 2020-09-17 | 2023-04-13 | Merck Sharp & Dohme Llc | Regimenes de dosificacion de anticuerpo anti-ilt4 o su combinacion con anticuerpo anti-pd-1 para el tratamiento de cancer. |
| EP3981789A1 (en) | 2020-10-12 | 2022-04-13 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Anti-lilrb antibodies and uses thereof |
| EP4232087A4 (en) * | 2020-10-21 | 2024-10-09 | Immune-ONC Therapeutics, Inc. | NOVEL ANTI-LILRB2 ANTIBODIES AND DERIVED PRODUCTS |
| CN117321083A (zh) * | 2021-03-11 | 2023-12-29 | 大学保健网 | Lilrb1和lilrb2结合分子及其用途 |
| CA3225139A1 (en) * | 2021-07-01 | 2023-01-05 | Albert Einstein College Of Medicine | Compositions and methods for inhibiting the expression of tmigd2 |
| CN119213023A (zh) * | 2022-03-29 | 2024-12-27 | 恩格姆生物制药公司 | Ilt3和cd3结合剂以及其使用方法 |
| WO2023235706A1 (en) * | 2022-05-31 | 2023-12-07 | Ngm Biopharmaceuticals, Inc. | Combination therapies using ilt-binding agents and pd-1 inhibitors |
| CN116333128B (zh) * | 2022-06-28 | 2026-03-24 | 北京科诺信诚科技有限公司 | 靶向人lilrb2的纳米抗体及其应用 |
| CN116082504A (zh) * | 2022-06-28 | 2023-05-09 | 北京科诺信诚科技有限公司 | 靶向人lilrb2的纳米抗体及其应用 |
| CN119604531A (zh) * | 2022-07-29 | 2025-03-11 | 盛禾(中国)生物制药有限公司 | 一种抗ilt4的单域抗体及其应用 |
| WO2024041315A1 (en) * | 2022-08-22 | 2024-02-29 | Antengene (Hangzhou) Biologics Co., Ltd. | Novel anti-lilrb2 antibodies and uses thereof |
| JP2025532504A (ja) * | 2022-09-08 | 2025-10-01 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｉｌｔ４抗体及びその医薬的使用 |
| KR20250090398A (ko) * | 2022-09-28 | 2025-06-19 | 스팍스 바이오사이언스 리미티드 | 백혈구 면역글로불린 유사 수용체 하위 패밀리 b 구성원 2(lilrb2)에 결합하는 항체 및 그 용도 |
| CN120548326A (zh) * | 2022-12-23 | 2025-08-26 | 艾奥麦克斯治疗公司 | 靶向白细胞免疫球蛋白样受体亚家族b1（lilrb1）和lilrb2的交叉特异性抗原结合蛋白（abp）、其组合和用途 |
| EP4491230A1 (en) * | 2023-07-14 | 2025-01-15 | iOmx Therapeutics AG | Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof |
| JP2026504928A (ja) * | 2023-01-20 | 2026-02-10 | ワシントン・ユニバーシティ | Ｌｉｌｒｂ４／ｉｌｔ３アンタゴニスト組成物およびその使用方法 |
| CN116789826A (zh) * | 2023-05-12 | 2023-09-22 | 南京师范大学 | 抗人lilrb2全人源单域抗体及其应用 |
| CN119176874A (zh) * | 2023-06-21 | 2024-12-24 | 康源博创生物科技(北京)有限公司 | 一种能够结合lilrb2的抗体或其抗原结合片段 |
| WO2025128822A1 (en) * | 2023-12-12 | 2025-06-19 | The Methodist Hospital | Lilrb3 modulators and methods of use thereof |
| GB202319149D0 (en) * | 2023-12-14 | 2024-01-31 | Kbio Holdings Ltd | Antibody |
| CN121299117B (zh) * | 2025-12-05 | 2026-03-27 | 中国农业科学院都市农业研究所 | 检测猪轮状病毒的试剂和纳米酶免疫层析试纸条及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014064287A1 (en) * | 2012-10-26 | 2014-05-01 | Deutsches Rheuma-Forschungszentrum Berlin | Bi-specific affinity reagents for cell-lineage-specific tnf-alpha neutralisation |
| US9429584B2 (en) * | 2013-02-28 | 2016-08-30 | National Cancer Center | Antibody against insoluble fibrin |
| US10138286B2 (en) | 2013-03-12 | 2018-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for inhibiting the effects of amyloid beta oligomers |
| KR20170007449A (ko) * | 2014-05-22 | 2017-01-18 | 프레드 헛친슨 켄서 리서치 센터 | 조혈 전구체 세포의 lilrb2 및 노치 매개 증식 |
| US20160200815A1 (en) * | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| AU2016229201B2 (en) * | 2015-03-06 | 2021-01-28 | The Board Of Regents Of The University Of Texas System | Anti-LILRB antibodies and their use in detecting and treating cancer |
| TWI780083B (zh) | 2016-11-18 | 2022-10-11 | 丹麥商賽門弗鎮公司 | 抗pd-1抗體及組成物 |
| TWI796329B (zh) * | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗－ilt4抗體及抗原結合片段 |
-
2019
- 2019-09-17 KR KR1020217011459A patent/KR20210108940A/ko not_active Withdrawn
- 2019-09-17 AU AU2019343131A patent/AU2019343131A1/en not_active Abandoned
- 2019-09-17 EP EP19863793.6A patent/EP3852805A4/en not_active Withdrawn
- 2019-09-17 WO PCT/US2019/051529 patent/WO2020061059A1/en not_active Ceased
- 2019-09-17 JP JP2021539483A patent/JP2022501428A/ja active Pending
- 2019-09-17 CA CA3111862A patent/CA3111862A1/en active Pending
- 2019-09-17 CN CN201980075255.5A patent/CN113543804A/zh active Pending
- 2019-09-17 US US17/276,324 patent/US12157768B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022501428A5 (https=) | ||
| US12215163B2 (en) | CD25 antibodies | |
| US20240002515A1 (en) | Methods and antibodies for modulation of immunoresponse | |
| JPWO2020061059A5 (https=) | ||
| JP6839761B2 (ja) | 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| KR102041832B1 (ko) | 췌장암의 치료 및/또는 예방용 의약 조성물 | |
| KR102052400B1 (ko) | 담낭암의 치료 및/또는 예방용 의약 조성물 | |
| CN109651507B (zh) | 一种激动型4-1bb单克隆抗体 | |
| US20170327580A1 (en) | Bispecific antibodies against cd3 epsilon and bcma for use in treatment of diseases | |
| JP2022546905A (ja) | 抗ｔｎｆｒ２抗体およびその使用 | |
| KR20190028716A (ko) | Pd-l1-특이적 항체 및 이를 사용하는 방법 | |
| CN114555637A (zh) | 针对ilt2的抗体及其用途 | |
| KR20230058074A (ko) | Ilt2에 대한 항체 및 이의 용도 | |
| CA3253669A1 (en) | Anti-CD39 antibodies and their use | |
| TW202529810A (zh) | 用於治療噬血球性淋巴組織細胞增生症之ｓｉｒｐ抗體 | |
| EP3583127B1 (en) | Anti-programmed death-ligand 1 (pd-l1) antibodies and therapeutic uses thereof | |
| SG11202111192TA (en) | Dosing regimens of bispecific cd123 x cds diabodies in the treatment of hematologic malignancies | |
| JP7681879B2 (ja) | Ｃｄ４３の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体 | |
| JP6881658B2 (ja) | Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療 | |
| TWI790193B (zh) | 調控免疫反應之方法及抗體 | |
| RU2793165C1 (ru) | Антитело против tnfr2 и его применение | |
| EP4103611B1 (en) | Bispecific antibodies binding hvem and cd9 | |
| HK40117648A (zh) | Il-18bp拮抗剂抗体及其在癌症治疗中的单一疗法和组合疗法中的用途 | |
| CN121605130A (zh) | 靶向btn3a和pd-1/pd-l1抑制轴的双特异性抗体 |